Fire Fox, I believe the reason the squamous patients were excluded in both the Avastin and Bavi first-line trials was due to a concern for adverse events. In the Bavi case I don't think there is any reason to think it would not work as well in the squamous cell type. If I remember correctly, this was a question put to Steve King at the annual shareholders meeting and he said that it would be something worth doing.
News 
Market Data 
Discover 
